<DOC>
	<DOCNO>NCT00424970</DOCNO>
	<brief_summary>The prevalence High Altitude Polycythemia ( Chronic Mountain Sickness ) 8 15 % high altitude region South America . There pharmacological treatment available . After first preliminary study 2003 demonstrate beneficial effect acetazolamide reduce hematocrit patient , 3 week treatment , want confirm effect implement treatment protocol 3 month-duration .</brief_summary>
	<brief_title>Treatment High Altitude Polycythemia Acetazolamide</brief_title>
	<detailed_description>Chronic mountain sickness ( CMS ) characterize excessive number red cell blood person live permanently altitude 2,500m . The symptom incapacitate disease : headache , chronic asthenia , digestive trouble , sleep disturbance . The hemoglobin concentration high 21 g/dl blood . In addition , patient show pulmonary hypertension variable degree , well systemic hypertension . This disease affect essentially male , woman also concern menopause . The evolution disease always dramatic , towards cardiac failure cerebral vascular stroke . The prevalence 8 % 15 % Andean Altiplano . No pharmacological treatment available . A preliminary study perform ( Richalet et al . AJRCCM , 2005 ) demonstrate efficiency acetazolamide ( carbonic anhydrase inhibitor ) reduce hematocrit erythropoetin concentration , increase nocturnal oxygen saturation patient suffer CMS , 3 week treatment . We plan perform double-blinded placebo-controlled study evaluate efficiency 3-month treatment daily 250 mg acetazolamide reduce hematocrit hemoglobin concentration ameliorate clinical symptom 55 patient suffer CMS live high altitude ( Cerro de Pasco , Peru ) .</detailed_description>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Hypoventilation</mesh_term>
	<mesh_term>Altitude Sickness</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<criteria>patient Chronic mountain sickness Hb &gt; 21g/dl patient smoker patient respiratory cardiovascular renal disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>high altitude</keyword>
	<keyword>hypoxia</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>polycythemia</keyword>
	<keyword>hypoventilation</keyword>
</DOC>